Cellectar Biosciences, Inc. Resources

News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • CLR 131
  • Clinical Trials
    • Overview
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Trial Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Trial Recruiting
    • Relapsed or Refractory Multiple Myeloma Clinical Trial Active, not recruiting
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study

Jul 17, 2018

Cellectar Announces 1-for-10 Reverse Stock Split

Jul 13, 2018

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma

Jul 9, 2018

Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial

Jun 28, 2018

Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131

Jun 7, 2018

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma

Jun 6, 2018

Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results

May 11, 2018

Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

May 9, 2018

Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma

May 2, 2018

Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma

Apr 17, 2018
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...26
    © 2021 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A